Morgan Stanley Upgrades Allergen (AGN) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Supreme Court divided over legality of patent reviews
November 27, 2017 11:34 AM ESTBy Andrew Chung
WASHINGTON (Reuters) - U.S. Supreme Court justices on Monday appeared divided over whether a federal agency's in-house process for challenging patents violates the constitutional rights of patent owners, leaving the fate of a system that has led to a high rate of patent cancellations uncertain.
In one of the most important Supreme Court patent cases in years, the nine justices heard an hour of arguments in a dispute over the U.S. Patent and Trademark Office's patent review proceeding, known as inter partes review (IPR). A decision to strike down the reviews could... More
Leerink Partners Resumes Allergen (AGN) at Outperform; Two Potential Blockbuster Absent from Valuation
November 27, 2017 6:29 AM EST(Updated - November 27, 2017 8:09 AM EST)
(updated to expand on analyst comments)
Leerink Partners resumes coverage on Allergen (NYSE: AGN) with a Outperform rating and a price target of $237.00.
Analyst Seamus Fernandez sees an emerging pipeline at a compelling... More
Barclays Starts Revance Therapeutic (RVNC) at Overweight
November 27, 2017 1:22 AM ESTBarclays initiates coverage on Revance Therapeutic (NASDAQ: RVNC) with a Overweight rating and a price target of $31.00.
Analyst Douglas Tsao comes out positive on the name citing a belief that the company's longer-acting toxin RT-002 will not displace Allergan's (NYSE:... More
